The decision to release a patient receiving medical treatments with unsealed radionuclides should take many factors into account, and is the balance among different requirements. The Italian legislative implementation of the new European Commission Basic Safety Standards (BSS) resulted in the recent Legislative Decree 101/2020, which sets specific dose constraints for the public and for carers and comforters. The aim of the present research is to assess acceptable release criteria (in terms of personal dose-equivalent rate at the moment of hospital discharge) to ensure compliance with the current regulatory framework in Italy. The MicroShield® code was used to derive a more realistic model for the emission of radioactivity by patients treated with radiopharmaceuticals. A geometric source-dependent correction factor, G(r), is introduced in order to take into account the volumetric distribution of the radionuclide into the human body and the attenuation of radiation from body tissues. The proposed approach has the potential to be routinely applied by clinic decision-makers to assess release criteria in the nuclear medicine practice.

Management of patients receiving radionuclide therapy with unsealed radionuclides: a proposed approach to the definition of release criteria in Italy

G. M. Contessa;S. Sandri;
2021-01-01

Abstract

The decision to release a patient receiving medical treatments with unsealed radionuclides should take many factors into account, and is the balance among different requirements. The Italian legislative implementation of the new European Commission Basic Safety Standards (BSS) resulted in the recent Legislative Decree 101/2020, which sets specific dose constraints for the public and for carers and comforters. The aim of the present research is to assess acceptable release criteria (in terms of personal dose-equivalent rate at the moment of hospital discharge) to ensure compliance with the current regulatory framework in Italy. The MicroShield® code was used to derive a more realistic model for the emission of radioactivity by patients treated with radiopharmaceuticals. A geometric source-dependent correction factor, G(r), is introduced in order to take into account the volumetric distribution of the radionuclide into the human body and the attenuation of radiation from body tissues. The proposed approach has the potential to be routinely applied by clinic decision-makers to assess release criteria in the nuclear medicine practice.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12079/59779
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
social impact